NT-0796

NT-0796 (ruvonoflast) is NodThera's lead asset - a brain-penetrant, oral small molecule that blocks NLRP3, the protein sensor that drives chronic low-grade inflammation in obesity and cardiometabolic disease [1]. NodThera is running two parallel Phase 2 cardiometabolic trials: RESOLVE-1 (NCT07055516), a 176-patient monotherapy study in obesity ± T2D with hsCRP as primary endpoint, and RESOLVE-2 (NCT07220629), a ~60-patient combination study with semaglutide [1][2]. Both trials are active and no longer recruiting; NodThera has guided to RESOLVE-1 readout Q3 2026 and RESOLVE-2 Q4 2026, with a Phase 3 registrational study planned for H1 2027 [9]. The thesis: GLP-1 agonists like Wegovy drive 15-20% weight loss but the residual cardiometabolic risk in obese patients tracks with inflammation. If NT-0796 can lower that inflammation on top of GLP-1, it carves out a defensible adjunct role. The risk is the same as every prior NLRP3 program: the target has clean genetics in rare autoinflammatory disease but has not yet produced an approved oral inhibitor for any common chronic condition.

Novel small molecule. Never approved anywhere. Phase 2. No public FDA breakthrough, fast-track, or orphan designations for the obesity program. NodThera is private - disclosed backers include Blue Owl Capital, Novo Holdings, F-Prime Capital, 5AM Ventures, Sofinnova Partners, Epidarex Capital, and Sanofi Ventures [7][9]. No public Series D announcement to date; cash runway through Phase 3 will likely require a partnership or additional financing - a real execution risk for a private sponsor planning a registrational study. Three trials matter for the obesity program. NCT06129409, a Phase Ib/IIa in 67 obese patients at cardiovascular risk, met its primary endpoint with an 82% mean hsCRP reduction and 76% of treated patients achieving hsCRP <2 mg/L - the gating evidence that pushed the program forward [3][9]. RESOLVE-1 (NCT07055516, n=176) is the monotherapy Phase 2 in obesity ± T2D with hsCRP ratio change as primary [2]. RESOLVE-2 (NCT07220629, ~60 patients) tests NT-0796 as an add-on to semaglutide with a composite primary [1]. NodThera also has a separate readout in Parkinson's disease (Clarke et al., Mov Disord 2025) - same molecule (dosed 300mg/day in the PD study), same mechanism, different tissue rationale [4]. That neuroinflammation paper is the strategic option value: if NLRP3 blockade matters in neurodegeneration, NodThera has a second shot on goal that doesn't depend on out-competing GLP-1s. Expected metabolic readouts Q3 2026 (RESOLVE-1) and Q4 2026 (RESOLVE-2) [9].

NLRP3 is a sensor protein inside immune cells that watches for cellular stress signals - misfolded proteins, cholesterol crystals, uric acid, ATP leaking from damaged cells. When triggered, NLRP3 assembles into the inflammasome, a protein complex that activates an enzyme called caspase-1 and chops two inflammatory cytokines, IL-1β and IL-18, into their active forms. It also drives pyroptosis, an inflammatory form of cell death. In obesity, fat tissue is chronically inflamed - macrophages infiltrate adipose, sense lipid overload, and fire NLRP3. The resulting IL-1β signaling drives insulin resistance and pancreatic beta-cell dysfunction. Blocking NLRP3 should, in theory, break that cycle. Genetic evidence for the target is strong: gain-of-function NLRP3 mutations cause CAPS (cryopyrin-associated periodic syndromes), rare autoinflammatory diseases where IL-1 blockade with anakinra or canakinumab works dramatically. CANTOS, the 10,000-patient canakinumab cardiovascular outcomes trial, showed anti-IL-1β reduced major cardiovascular events in patients with elevated hsCRP - direct human evidence that the IL-1 axis matters in cardiometabolic disease [5]. The question for NT-0796 is whether oral, brain-penetrant NLRP3 blockade can replicate that benefit without the infection risk that derailed canakinumab's commercial trajectory. Brain penetration matters because hypothalamic inflammation drives leptin resistance and feeding behavior - NodThera's pitch is that you can hit the central regulator of appetite, not just peripheral fat.

RESOLVE-2 (NCT07220629) is a Phase 2a, randomized, double-blind, placebo-controlled study in approximately 60 obese patients on stable GLP-1 receptor agonist therapy (semaglutide). The primary endpoint is a composite that includes changes in multiple inflammatory and metabolic biomarkers, safety and tolerability, and change in body weight - not a pure safety study [1][9]. That composite is a more informative readout than a conventional Phase 2a safety primary, because mechanistic and efficacy signals enter the primary analysis rather than sitting downstream as secondaries. RESOLVE-1 (NCT07055516, n=176) is the cleaner mechanistic read: obesity with and without T2D, primary endpoint hsCRP ratio change [2][9]. If NT-0796 doesn't lower hsCRP at scale here, the drug isn't engaging the inflammasome meaningfully in this population. Weight loss, HbA1c, and HOMA-IR (a calculated measure of insulin resistance derived from fasting blood glucose and insulin) sit as secondaries. Both trials are active and no longer recruiting, meaning enrollment completed. The Phase Ib/IIa study (NCT06129409, n=67) already showed an 82% mean hsCRP reduction with 76% of patients reaching hsCRP <2 mg/L in obese patients at cardiovascular risk, so the Phase 2 hsCRP readout has a strong prior probability of replicating peripheral target engagement [3][9]. The design concern is the comparator on RESOLVE-2: adjunct to semaglutide, not head-to-head - the question is whether NT-0796 adds anything detectable on top of GLP-1's potent weight loss. Detecting incremental 2-3% weight loss in a ~60-patient trial is statistically hard, so the cleanest efficacy signal will come from biomarkers (hsCRP, HOMA-IR) rather than scale weight. The 300mg/day dose used in the Parkinson's study [4] is a reasonable benchmark for the obesity program, though NodThera has not publicly confirmed identical dosing in RESOLVE-1/2.

Our model estimates an 8% chance this drug is eventually approved. It starts from the historical approval rate for Phase 2 drugs in this area-about 35%-then adjusts based on ten facts about the trial and sponsor. The estimate is nudged up by more secondary endpoints than usual, but pulled down by the sponsor's weak approval record, limited earlier-phase results, and heavier-than-usual blinding. The remaining factors fall near average, so they leave the number close to where it started.

Efficacy risk first. Lowering hsCRP shows target engagement, not clinical benefit. Translating an anti-inflammatory mechanism into measurable weight loss on top of semaglutide is the hard part - GLP-1 agonists already deliver 15-20% weight loss, and any add-on must clear that noise floor in small trials. RESOLVE-2's composite primary is a partial hedge - biomarkers and weight enter the primary analysis - but a clean hsCRP win without weight or metabolic differentiation will not unlock Phase 3 funding. Safety risk is harder. NLRP3 is part of innate immune defense against bacterial and fungal infections. Anti-IL-1 biologics like canakinumab caused a measurable uptick in fatal infections in CANTOS, which was a key reason Novartis abandoned the cardiovascular indication despite positive efficacy [5]. Whether NT-0796's tissue distribution and partial inhibition profile avoids that is unknown. Brain penetration adds CNS off-target questions - mood, cognition, sleep - that won't surface in 12-week obesity readouts. Execution risk is moderate-to-high: NodThera is private, small, and planning a Phase 3 registrational study to start H1 2027 [9]. There is no public Series D announcement; the company likely needs additional capital or a partnership to fund cardiovascular outcomes trials at CANTOS scale. Commercial risk is the killer. Even if RESOLVE-1/2 hit, the obesity market is dominated by Novo Nordisk and Lilly's GLP-1 and multi-agonist programs. An oral adjunct needs payer-relevant differentiation - cardiovascular event reduction, prevention of GLP-1 weight regain, or selective hypothalamic effects on appetite. Without that, NT-0796 stays niche and commands little pricing power against semaglutide. On semaglutide patent timing: the US composition-of-matter patent (with PTE) expires April 20, 2031, but Novo Nordisk holds a patent thicket - formulations, dosing, delivery - that pushes likely US Wegovy generic entry toward the mid-to-late 2030s, with some estimates as late as 2041 [10]. The patent cliff is contested and jurisdiction-dependent; investors modeling NT-0796 pricing power against branded versus generic GLP-1s should treat this as a wide-uncertainty variable, not a clean 2031 date.

Worth watching, conditionally. The signal to wait for is the RESOLVE-1 (NCT07055516) Q3 2026 readout - if hsCRP drops meaningfully in 176 obese patients, NodThera has confirmed mechanism in the target population at scale, and the question shifts from 'does the drug work' to 'does it matter on top of semaglutide' [2][9]. That's the trial that determines whether this program is fundable through Phase 3 or quietly shelved. RESOLVE-2's Q4 2026 readout will then test whether benefit stacks on top of GLP-1; the composite primary means a clean miss on safety, biomarkers, and weight together would be unambiguously negative [1][9]. Any infection imbalance or CNS adverse events would echo the canakinumab problem and effectively kill the chronic-disease use case [5]. Check back at NodThera corporate updates (private company, so news comes via press releases or investor decks) and watch ClinicalTrials.gov for results posting. The Clarke et al. Parkinson's paper is the asymmetric upside - same brain-penetrant molecule (300mg/day in PD), neuroinflammation rationale, very different competitive set [4]. The realistic outcome is a partnership with a metabolic player (Novo, Lilly, Pfizer, or BI) if the hsCRP read is clean, with Phase 3 cardiovascular outcomes economics requiring Big Pharma backing. NodThera alone cannot fund a CANTOS-scale trial. The competitive landscape on NLRP3 itself has consolidated around Roche (two assets post-Inflazome: inzomelid and selnoflast) as the best-capitalized rival [8]. For BioCosm tracking purposes: this is a real shot at validating NLRP3 in a common chronic disease, but the burden of proof is high and the commercial path narrow.